drugset / Trial / NCT02005991

A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377

NCT02005991

Phase 1 Completed 4 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will see how PF-05212377, an experimental drug to treat symptoms from Alzheimer's Disease, distributes in the brain after one dose of PF-05212377 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-05212377 in these subjects and will measure the level of PF-05212377 in the blood.

Timeline

Start
2013-11
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05212377 Small molecule 10 mg Oral
Subject PF-05212377 Small molecule 20 mg Oral
Subject PF-05212377 Small molecule 70 mg Oral

Indications

No indication recorded.